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ABSTRACT
Jansen’s metaphyseal chondrodysplasia (JMC) is a rare disease of bone and mineral ion physiology that is caused by activating muta-
tions in PTHR1. Ligand-independent signaling by the mutant receptors in cells of bone and kidney results in abnormal skeletal
growth, excessive bone turnover, and chronic hypercalcemia and hyperphosphaturia. Clinical features further include short stature,
limb deformities, nephrocalcinosis, and progressive losses in kidney function. There is no effective treatment option available for JMC.
In previous cell-based assays, we found that certain N-terminally truncated PTH and PTHrP antagonist peptides function as inverse
agonists and thus can reduce the high rates of basal cAMP signaling exhibited by the mutant PTHR1s of JMC in vitro. Here we
explored whether one such inverse agonist ligand, [Leu11,dTrp12,Trp23,Tyr36]-PTHrP(7-36)NH2 (IA), can be effective in vivo and thus
ameliorate the skeletal abnormalities that occur in transgenic mice expressing the PTHR1-H223R allele of JMC in osteoblastic cells
via the collagen-1α1 promoter (C1HR mice). We observed that after 2 weeks of twice-daily injection and relative to vehicle controls,
the IA analog resulted in significant improvements in key skeletal parameters that characterize the C1HRmice, because it reduced the
excess trabecular bone mass, bone marrow fibrosis, and levels of bone turnover markers in blood and urine. The overall findings pro-
vide proof-of-concept support for the notion that inverse agonist ligands targeted to the mutant PTHR1 variants of JMC can have
efficacy in vivo. Further studies of such PTHR1 ligand analogs could help open paths toward the first treatment option for this debil-
itating skeletal disorder. © 2019 American Society for Bone and Mineral Research.
KEY WORDS: CELL/TISSUE SIGNALING - ENDOCRINE PATHWAYS; PTH/VIT D/FGF23; ANIMAL MODELS; GENETIC ANIMAL MODELS; THERAPEUTICS;
HORMONE REPLACEMENT/RECEPTOR MODULATORS
Introduction
Jansen’s metaphyseal chondrodysplasia (JMC)
(1) is a rare disor-
der of bone and mineral ion physiology caused by activating
mutations in parathyroid hormone receptor-1 (PTHR1).(2) Clinical
hallmarks of the disease include short stature, deformed, under-
mineralized bones, chronic hypercalcemia and hyperphospha-
turia with normal serum PTH levels, and elevated serum
markers of bone turnover.(3–7) Disease features become appar-
ent within days or months after birth and progress with age.(6,7)
The overall disease profile is consistent with the critical roles that
the PTHR1 plays in endochondral bone formation,(8) and in cal-
cium and phosphate homeostasis; processes that are normally
controlled by the two endogenous peptide ligands, PTH-related
protein (PTHrP) and PTH, respectively.(9) There is currently no
effective treatment option available for JMC patients.
PTHR1 is a family B G-protein-coupled receptor (GPCR) and, as
for each of these receptors, binds its agonist peptide ligands,
such as the bioactive PTH(1-34) fragment, via a two-site mecha-
nism. This mechanism involves an initial docking of the (15-34)
portion of the ligand to the amino-terminal extracellular domain
(ECD) portion of the receptor and a subsequent engagement of
the N-terminal (1-14) portion of the ligand with the extracellular
loop and seven–transmembrane helical domain (TMD) region of
the receptor, which leads to receptor activation.(10,11) The recent
high-resolution X-ray crystal(12) and cryogenic electron
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microscopy (cryo-EM)(13) structures of the PTHR1, each in com-
plex with a PTH(1-34) or PTHrP(1-36) analog ligand, confirm
and extend this model of ligand binding. These structures thus
show the peptide to be bound as a linear α-helix with its C-
terminal portion docked to the ECD and its N-terminal portion
projecting into the core of the TMD bundle. This binding mode
is similar to that seen in the high-resolution structures reported
for several other family B GPCRs, including the receptors for glu-
cagon, GLP-1, and calcitonin, each in complex with a bound pep-
tide ligand,(14–18) thus supporting a common basic mechanism
of ligand-induced activation used by each of the family B GPCRs.
All of the knownmutations that cause JMCmap to one of three
residue positions in PTHR1, each of which is located at the cyto-
solic base of a TMD helix: His223 in TM helix (TM) 2, Thr410 in
TM6, and Ile458 in TM7.(2,19) The residues at these positions are
highly conserved in the family B GPCRs. The PTHR1 mutations
of JMC can thus be predicted to perturb a critical component of
the receptor located in the lower portion of the TMD bundle that
controls receptor activation and deactivation.(11–13,20)
Inverse agonists are a subclass of antagonist ligands that can
bind to an active-state receptor and revert it to an inactive
conformation.(21–23) A number of competitive antagonist ligands
for the PTHR1 developed from the PTH(7-34) or PTHrP(7-36)
fragments(24–26) have been shown to function as inverse ago-
nists in vitro and can thus suppress the basal rates of cAMP sig-
naling in transfected COS-7 or HEK293 cells expressing a PTHR1
variant of JMC.(27–29) Here, we explore the hypothesis that such
an inverse agonist analog can be effective on a PTHR1 mutant
of JMC in vivo. We thus assessed the capacity of [Leu11,dTrp12,
Trp23,Tyr36]-PTHrP(7-36)NH2, a peptide shown to act as a potent
inverse agonist in vitro,(28,29) to rescue the skeletal abnormalities
that occur in transgenic mice expressing the PTHR1-H223R allele
of JMC in osteoblasts.(30) These mice exhibit a marked skeletal
phenotype characterized principally by excess bone mineral
density in the marrow compartments. Although the inverse ago-
nist treatment did not completely reverse the mutant pheno-
type, we did observe, with only 2 weeks of intermittent dosing,
significant improvements in a number of the key features of
the mutant skeletal phenotype.
Materials and Methods





{PTH(1-34)} were synthesized by the Massachusetts General Hos-
pital Biopolymer Core facility. Peptides were HPLC-purified and
confirmed by mass spectroscopy. GHR-10 cells(29) are derived
from HEK293 cells by stable transfection to expresses the
luciferase-based pGlosensor-22F (GloSensor®; Promega, San Luis
Obispo, CA, USA) cAMP reporter and the PTHR1-H223R mutant
allele of JMC.
Functional assessment of inverse agonism in cultured cells
GHR-10 cells were seeded into white, clear-bottomed 96-well
plates and used for assay 24 to 48 hours after the cell monolayers
became confluent. For assay, the cells were preloaded with lucif-
erin for 20 min at room temperature in CO2-independent media
(ThermoFisher Scientific, Waltham, MA, USA) and then treated
with ligand at varying concentrations in media or media alone
and luminescence was measured at 2-min intervals using a
PerkinElmer Envision plate reader. For dose-response curves,
the area-under-the-curve (AUC) of the time course-luminescence
response at each ligand concentration was expressed as a per-
cent of the response observed in the absence of ligand and plot-
ted versus ligand concentration. Data from three independent
experiments with duplicate wells in each were combined as
means  SD.
Mouse breeding and maintenance
Collagen1a1-PTHR1-H223R transgenic (C1HR) mice(30) in strain
FVB were maintained by mating heterozygous C1HR males to
wild-type FVB females (Charles River Laboratories, Worcester,
MA, USA; cat #207FVB). Genotypes were determined by PCR of
genomic DNA obtained from tail tissue using 50-GAGTCTA-
CATGTCTAGGGTCTA-30 and 50-TAGTTGGCCCACGTCCTGT-30 as
forward and reverse primers, respectively. The mice were housed
in facilities operated by the Center for Comparative Medicine of
the Massachusetts General Hospital, and all experimental proce-
dures were approved by the MGH Institutional Animal Care and
Use Committee and in compliance with federal, state, and local
animal care rules and guidelines. C1HR mice and wild-type litter-
mates were maintained on normal chow with a soft diet supple-
ment (DietGel 76A plus DietGel Boost; Clear H2O, Portland, ME,
USA), which was provided due to the oversized incisors in the
C1HR mice. Heterozygous C1HR mice and wild-type littermate
controls were assigned randomly to treatment groups. Power cal-
culations predicted that the number of animals used per study
group would be sufficient to detect statistically significant differ-
ences in intended primary experimental outcomes (ie, changes in
bone structural and cellular parameters, blood and urinemarkers,
and mRNA levels).(30,31)
Peptide preparation and injection
A stock solution of [Leu11,dTrp12,Trp23,Tyr36]-PTHrP(7-36)NH2
was prepared in 10mM acetic acid at a peptide concentration
of 2.0 × 10−3 M. For injection, the stock solution was diluted in
vehicle (150mM NaCl, 10mM citrate, 0.05% Tween80, pH 5.0) to
a peptide concentration of 2.0 × 10−4 M. Mice were injected
twice daily (BID) subcutaneously into the interscapular area with
each injection at a peptide dose of 500 nmol (1.9 mg)/kg body
weight. The injection volume was 2.5 mL/kg, corresponding to
10 to 26 μL per mouse, depending on body weight, which, at
age 24 days, was 12.9  1.3 g (n = 17) and 6.8  0.8 g (n = 19;
mean SD) for wild-type and C1HR mice, respectively. The pep-
tide injection dose was selected to be as high as practical given
limits of peptide solubility (~7.0 mg/mL), the expected rapid rate
of clearance of the peptide from the circulation,(24) a rapid rate of
dissociation from the receptor,(28) and the goal of achieving as
close tomaximumoccupancy of themutant receptor as possible.
In prior studies, we found that injection of PTH(1-34) at a dose of
50 nmol/kg into wild-type mice was sufficient to induce a frank
hypercalcemic response,(32) indicating effective ligand occu-
pancy of the PTHR1 in target tissue. We thus predicted at least
some occupancy of the mutant PTHR1-H223R would be
achieved by the current inverse agonist peptide when injected
at a 10-fold higher dose than used in the prior study for PTH
(1-34). Control animals were injected with vehicle at the same
injection volume (2.5 mL/kg). Mice were injected for 17 days at
approximately 12-hour intervals beginning at 7 days of age. At
12 hours after the last injection, the mice were euthanized, and
tissue samples were dissected for analysis.
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To double-label the bone surfaces for dynamic histomorpho-
metric analyses, the mice were injected intraperitoneally with
calcein (20 mg/kg) and then demeclocycline (40 mg/kg) at
48 and 24 hours prior to euthanasia, respectively. The 24-hour
labeling interval was selected based on the expected high rate
of bone formation and turnover in the C1HR mice,(30) and
although the interval was too short to give consistent dual bands
of labels in the wild-type mice, it did yield adequate dual fluores-
cent labels in the C1HR mice.
Blood biochemistry
Blood was collected from the mice prior to euthanasia. Plasma
total calcium was determined using a Calcium LiquiColor Test
kit (Stanbio Laboratory, Boerne, TX). Plasma inorganic phosphate
was determined using a Phosphate Colorimetric Assay Kit
(BioVision, Inc, San Francisco, CA, USA). Plasma C-terminal telo-
peptides of type I collagen (CTX1) was determined using the
RatLaps EIA kit (Immunodiagnostic Systems Inc., Fountain Hills,
AZ, USA).
Histology
Tibias were harvested, fixed with 10% formalin overnight and
then washed in PBS and transferred to 70% EtOH. The fixed non-
decalcified tibias were dehydrated (graded ethanol) and subse-
quently infiltrated and embedded in methylmethacrylate.
Longitudinal sections (5μm) were cut and stained with Goldner’s
Trichrome for measurements of cellular parameters, and by the
method of von Kossa(33) to evaluate bone mineralization.
Dynamic bone parameters were evaluated on unstained sections
bymeasuring the extent and the distance between double labels
using the Osteomeasure analyzing system (Osteometrics Inc.,
Decatur, GA, USA). The structural, dynamic, and cellular parame-
ters were evaluated using standardized guidelines.(34)
Micro–computed tomography
Microcomputed tomography (μCT) analysis was performed on
dissected bones using a desktop microtomographic imaging
system (μCT 40; Scanco Medical AG, Brüttisellen, Switzerland).
Samples were scanned with a 10-μm isotropic voxel size, 70-kV
peak potential (kVp), 114-μA X-ray tube intensity, and 300-ms
integration time. Intramedullary bone and total volume were
assessed in the distal femoral metaphysis in a region beginning
at the peak of the growth plate and extending proximally for
1.0 mm (100 transverse slices) as well as in a region of the prox-
imal tibial metaphysis beginning 0.1 mm inferior to the growth
plate and extending distally for 1.0 mm (100 transverse slices).
At the femoral mid-shaft, analysis was performed on a 0.5-mm-
long region (50 transverse slices) tomeasuremedullary total area
(Ma.TA) and medullary bone area (Ma.BA); the Ma.BA was nor-
malized to the Ma.TA at each slice, and the mean value reported
as the medullary bone area fraction (Ma.BA/TA).
Quantitative real-time (RT) PCR of bone cell mRNAs
Total RNA was prepared from femoral diaphyses with epiphyses
and perichondrium removed and the marrow left unflushed. The
bones were homogenized in TRIzol using a Dremel Tissue Tearor
homogenizer (Dremel, Racine, WI, USA), and total RNA was
extracted by phase separation with chloroform followed by pre-
cipitation in isopropanol and then purified using an RNAeasy
Mini kit (Qiagen, Hilden, Germany). The total RNA was then
reversed-transcribed and the cDNA was processed using a
TaqMan® quantitative RT-PCR system (TaqMan® Gene Expres-
sion Assays; Thermo Fisher Scientific, Waltham, MA, USA). For
each gene, the measured mRNA level in each sample was nor-
malized to the level of 18S rRNA in that sample and then
expressed relative to the normalized level of that mRNA
observed in the samples from vehicle-treated wild-type mice.
The TaqMan® probes used are shown in Supporting Fig. S5.
Data analysis
Data were processed using Microsoft Excel-2016 (Redmond, WA,
USA) and GraphPad Prism 8.2 (La Jolla, CA, USA) software pack-
ages. Statistical analyses were performed (Prism) using a one-
way ANOVA with Tukey’s post hoc comparisons of means when
ANOVA was significant. Values of p <.05 indicate significance.
Results
Inverse agonist properties in vitro
The primary structure of [Leu11,dTrp12,Trp23,Tyr36]-PTHrP(7-36)
NH2
(28,29) and its mode of action on the PTHR1-H223R mutant
of JMC are depicted in Fig. 1A. In functional studies in vitro,
[Leu11,dTrp12,Trp23,Tyr36]-PTHrP(7-36)NH2 was more effective as
an inverse agonist than the PTH-based analog, [Nle8,18,dTrp12,
Tyr34]-bPTH(7-34)NH2,
(24,25) because it more effectively reduced
basal cAMP signaling in HEK293 cells stably transfected to
express PTHR1-H223R and the GloSensor cAMP reporter
(Fig. 1B,C). Based on these and prior cell-based studies(28,29)
[Leu11,dTrp12,Trp23,Tyr36]-PTHrP(7-36)NH2 was selected for the
studies in vivo described in the following sections.
Properties of Col1-PTHR-H223R mice and peptide dose
selection
Col1-H223R transgenic mice (referred to as C1HR mice herein)
express the PTHR1-H223R variant under the control of the col-
lagen1a1 promoter, which is active predominantly in osteo-
blasts.(30) Compared to wild-type mice, C1HR mice exhibit a
pronounced accumulation of trabecular bone in the marrow
compartments of the long bones, a thinning of the bone cortices,
an accumulation of fibrotic stromal cells in the marrow spaces
between bone trabeculae, and high rates of bone turn-
over.(30,31,35) In a pilot study, we found that once-daily injection
of [Leu11,dTrp12,Trp23,Tyr36]-PTHrP(7-36)NH2, henceforth
referred to as inverse agonist or IA, into the C1HR mice for
2 weeks at a daily dose of 500 nmol/kg did not result in any
noticeable change in the bone phenotype, as assessed histolog-
ically at the proximal tibias. For the current experiment, we
sought to increase ligand exposure and thus injected the mice
BID with the IA analog at a dose of 500 nmol/kg/injection. The
injections were started on postnatal day 7 and continued every
12 hours for 17 days. As controls, C1HR littermate mice were
injected with vehicle, and wild-type littermates were injected
with either vehicle or inverse agonist. The C1HRmice were small,
with body weights that were about 60% less than that of their
wild-type littermates, as reported.(30) For either the wild-type or
C1HR mice, no change in mean body weight occurred with
inverse agonist treatment, as compared to with vehicle treat-
ment (Supporting Fig. S1A), and the overall health appearance
of the mice did not change over the 17-day treatment period.
Twelve hours after the last injection, the mice were euthanized
and bones as well as blood and urine samples were collected
for analysis.
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Inverse agonist treatment reduces bone mass and
increases bone length in C1HR mice
μCTwas used to assess the effects of inverse agonist treatment on
bone mineral density and bone structure in the C1HR mice. μCT
scans of the femurs and tibias isolated from the vehicle-treated
C1HR mice revealed the expected marked increases in trabecular
bone in themetaphyseal regions of the distal femur and proximal
tibia, as well as in the medullary region of the femur mid-shaft, as
compared to the corresponding regions of the bones isolated
from vehicle-treated wild-type mice (Fig. 2A,B, Supporting
Figs. S1B and S2). Quantification of bone volume fraction
(BV/TV, %) and bone mineral density (mg hydroxyapatite/cm3)
in the metaphyseal regions of the distal femurs and proximal tib-
ias, and of cross-sectional bone area at the femoral mid-shaft con-
firmed this increase in bone in the vehicle-treated C1HR mice
relative to the vehicle-treated wild-type mice (Fig. 2C). Signifi-
cantly less bone was measured in these compartments of the
femurs and tibias obtained from C1HR mice treated with inverse
agonist, as compared to the bones from vehicle-treated C1HR
mice (Fig. 2A–C, Supporting Figs. S1B and S2). No change in these
structural parameters was observed in the bones obtained from
wild-type mice treated with inverse agonist, as compared to
those obtained from wild-type mice treated with vehicle.
Inverse agonist treatment reduces osteoblast number,
bone marrow fibrosis, and bone formation rates in
C1HR mice
We further explored the effects of the inverse agonist on bone
properties by examining histological sections of the proximal tib-
ias obtained from the mice. Consistent with the μCT imaging,
staining of the tibia sections with von Kossa dye revealed the
expected increase in mineralized trabecular bone in the tibias
of the vehicle-treated C1HR mice, as compared to those of the
vehicle-treated wild-type mice, and this trabecular bone mass
was reduced in the C1HR mice by inverse agonist treatment
(Fig. 3A). Higher magnification views of sections stained with
the Goldner’s Trichrome reagent revealed the expected accu-
mulation of fibrotic, stromal-like cells in the intertrabecular
spaces in the tibias from the vehicle-treated C1HR mice,
whereas these spaces in bones from wild-type mice were pop-
ulated by smaller hematopoietic-type cells(30,31,35,36) (Fig. 3B).
Fig. 1. Properties of the inverse agonist ligand. (A) The primary structure of the inverse agonist analog used for in vivo studies, [Leu11,dTrp12,Trp23,Tyr36]-
PTHrP(7-36)NH2,
(28) with residues not native to human PTHrP shown in blue circles, and amodel of inverse agonism. The H223Rmutation of JMC is located
at the base of TM helix 2 and induces an active-state receptor conformation that mediates ligand-independent GαS coupling and cAMP signaling; binding
of the inverse agonist reverts the receptor to an inactive conformation and decreases basal signaling. (B) Inverse agonist responses in HEK293 cells stably
expressing PTHR1-H223R and the GloSensor cAMP reporter (GHR-10 cells); the cells were treated with [Leu11,dTrp12,Trp23,Tyr36]-PTHrP(7-36)NH2 {dTrp
12-
PTHrP (7-36)} or the PTH-based antagonist/inverse agonist, [dTrp12,Nle8,18,Tyr34]-bPTH(7-34)NH2
(25) {dTrp12-PTH(7-34)}, each at 100nM, or with vehicle, and
cAMP-dependent GloSensor luminescence was recorded at 2-min intervals for 22 min. (C) Dose-response curves generated from the areas-under-the-
curve of time-course data obtained as in B at varying concentrations of ligand. Data are means  SD of three experiments, each in duplicate.
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Treatment with the inverse agonist reduced the abundance
of these fibrotic cells in the tibiae of the C1HR mice, as com-
pared to the amounts of these cells seen in the tibias from
the C1HR mice injected with vehicle, and there was concom-
itantly an apparent increase in the abundance of smaller
hematopoietic-type cells (Fig. 3B). Quantitative histomor-
phometric analyses confirmed these observations, as inverse
agonist treatment, relative to vehicle treatment in the C1HR
mice significantly reduced the measured bone mass, the
number of bone trabeculae, as well as the amount of marrow
cell fibrosis (Fig. 3C, Supporting Table S1). Inverse agonist
treatment in C1HR mice also reduced the number of osteo-
blasts per unit length of bone perimeter, whereas it
increased the number of osteoclasts; the latter effect could
be explained by a reduction in the total bone area in the
C1HR mice with a corresponding smaller change in the total
number of osteoclasts in the measured area (Fig. 3C,
Supporting Table S1).
Fig. 2. μCT analysis of the effects of inverse agonist treatment on bone density in WT and C1HRmice. Femurs and tibias isolated fromWT and C1HRmice
after 17 days of treatment with inverse agonist, IA, or Veh were analyzed by μCt. (A) Representative sagittal views of the whole femur. (B) Representative
sagittal views and corresponding transverse views of the proximal tibia. (C) Quantification of trabecular BV/TV (%) and BMD (mg hydroxyapatite/cm3) at
the distal femur and proximal tibia, and of cross-sectional medullary BA/TA (%) at the femur mid-shaft. Measurements were made between the cortices in
the regions of interest shown by the boxes in the vehicle-treated WT images in A and B. Data are means SD; p values (Tukey’s multiple comparison test
after ANOVA) are shown for paired groupsmarked by brackets (n = 8–10 per group). μCT =micro–computed tomography; C1HR = Col1-PTHR1-H223R; WT
= wild-type; Veh = vehicle; IA = [Leu11,dTrp12,Trp23,Tyr36]-PTHrP(7-36)NH2; BV/TV = bone volume relative to tissue volume; BMD = bone mineral density;
BA/TA = bone area relative to total area.
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The differences given in the previous paragraph in bone struc-
tural parameters observed in the C1HRmice treated with or with-
out inverse agonist likely reflect, at least in part, effects on rates
of bone formation. To assess rates of bone mineralization and
formation, the mice were sequentially injected with the fluores-
cent bone-labeling dyes, calcein and demeclocycline, at two
days and one day, respectively, before the last injection (day
17). The 24-hour interval between dye injections was selected
based on the higher bone formation rate predicted for the
C1HR mice from previous studies.(30,31) This interval was too
short to provide consistent double labels in the bones of wild-
type mice, which precluded reliable rate measurements in the
bones of these animals. In the bones of the C1HRmice, adequate
double labels were obtained, and the distances measured
Fig. 3. Histological analysis of the effects of inverse agonist treatment on bone inWT and C1HRmice. Tibias isolated fromWT and C1HRmice after 17 days
of treatment with IA or Veh were analyzed histologically in the proximal region. (A) Representative sagittal views of sections stained with von Kossa dye to
show mineralized bone tissue (magnification ×40). (B) Higher magnification (×400) views of sections stained with Goldner’s trichrome dye to show bone
trabeculae (green) and surrounding cells and tissue. Blue arrows in the C1HR + Veh image point to areas of stromal cell fibrosis; yellow arrows point to
osteoclasts. (C) Quantification of histomorphometric parameters in a region just below the center of the growth plate in the proximal tibia. Mineral appo-
sition rate was not determined in bones of WTmice due to inadequate separation of double labels. Data are means SD; p values (Tukey’s multiple com-
parison test after ANOVA) are shown for paired groups marked by brackets (n = 8–10 per group). Additional histomorphometric data are shown in
Supporting Fig. S3 and Supporting Table S1. WT = wild-type; C1HR = Col1-PTHR1-H223R; IA = inverse agonist; Veh = vehicle.
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between the two labels clearly indicated that inverse agonist
treatment reduced the rates of bone mineral apposition and
bone formation in C1HR mice (Fig. 3C, Supporting Fig. S3B, Sup-
porting Table S1).
Inverse agonist treatment reduces markers of bone
turnover in C1HR mice
Serum levels of carboxy-terminal crosslinked telopeptide of type
I collagen (CTX1) were significantly elevated in the vehicle-
treated C1HR mice, as compared to the levels in the vehicle-
treated wild-type mice, and these levels in C1HR mice were
reduced by inverse agonist treatment (Fig. 4A). Serum concentra-
tions of total calcium (Ca) were not different between the four
groups, whereas serum inorganic phosphorus (Pi) was
unchanged between groups of wild-type mice and the vehicle-
treated C1HR mice but was significantly reduced in C1HR mice
treated with the inverse agonist, as compared to C1HRmice trea-
ted with vehicle (Fig. 4B,C). Urine levels of both Ca and Pi were
significantly elevated in vehicle-treated C1HR mice, and were
reduced in the C1HR mice by inverse agonist treatment,
although the effect was significant only for urine Ca (Fig. 4D,E).
The elevations in urine Ca and Pi, and plasma CTX1 observed in
the vehicle-treated C1HR mice, as compared to the levels in
wild-type mice, are consistent with an increase in the rate of
osteoclast-mediated bone resorption, as induced indirectly by
the constitutive signaling activity of the mutant PTHR1-H223R
in bone osteoblasts, whereas the reductions in these markers
with inverse agonist treatment are consistent with a suppression
of PTHR1-H223R signaling activity in the osteoblasts of the trans-
genic mice and an indirect suppression of osteoclast-mediated
bone turnover.
The levels of mRNAs encoding several osteoblast-produced
proteins that are regulated by PTHR1 signaling, including
collagen-1a1, the receptor activator of nuclear factor-kappaB
ligand (RANKL), which stimulates osteoclast differentiation and
activity, and osteoprotegerin (OPG), which inhibits RANKL by act-
ing as a decoy receptor,(37) as well as the osteoclastic gene prod-
uct, tartrate-resistant acid phosphatase 5b (TRAP5b), were
elevated in femurs isolated from vehicle-treated C1HR mice, as
compared to femurs isolated from vehicle-treated wild-type
mice (Supporting Fig. S4). Inverse agonist treatment had only a
minor if any effect on the levels of these mRNAs in C1HR mice,
although collagen-1a1 mRNA levels were reduced signifi-
cantly (p = .048).
DISCUSSION
Because JMC is an ultra-rare disease, with only about 30 cases
identified since its first description in 1934,(1,7) it has garnered lit-
tle if any interest from the pharmaceutical industry in terms of
therapeutic development. There is thus no effective drug ther-
apy available for the disease, despite a clear medical need(6)
and precise knowledge of the molecular target.(27,38,39) Those
considerations provided the key impetus for the current study,
which is the first time that an inverse agonist ligand for a consti-
tutively active mutant PTHR1 has been tested in vivo. The overall
results provide proof-of-concept support for the hypothesis that
such an inverse agonist ligand can be effective at suppressing
the constitutive activity of a JMC PTHR1 variant in vivo. We thus
found that administration of [Leu11,dTrp12,Trp23,Tyr36]-PTHrP
(7-36)NH2 to C1HR mice expressing the PTHR1-H223R mutant
allele in osteoblasts can prevent and/or correct at least some of
Fig. 4. Effects of inverse agonist treatment on markers of bone and mineral metabolism in blood and urine. Blood and urine samples collected from WT
and C1HRmice after 17 days of treatment with IA or Veh were analyzed for CTX1 (A), total calcium (B, D), and Pi (urine values are normalized to creatinine)
(C, E). Data are means  SD; p values (Tukey’s multiple comparison test after ANOVA) are shown for paired groups marked by brackets (n = 8–10 per
group). WT = wild-type; C1HR = Col1-PTHR1-H223R; IA = inverse agonist; Veh = vehicle; Pi = inorganic phosphate.
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the skeletal and mineral ion abnormalities that otherwise occur
in these JMC model mice.
We selected the [Leu11,dTrp12,Trp23,Tyr36]-PTHrP(7-36)NH2
analog for use in this study because of its proven effectiveness
in suppressing the basal cAMP signaling activity of the
PTHR1-H223R mutant in transfected cells.(28,29) The C1HR trans-
genic mice were used as a model of JMC because they express
the PTHR1-H223R mutant allele, which is the most common
JMC disease variant,(7) and they exhibit a robust, well-
characterized phenotype in skeletal tissue, which is the main site
affected in patients. After only 17 days of treatment the inverse
agonist produced significant reductions in the excess trabecular
bone mass that otherwise accumulates in the long bones of the
C1HR mice. It also quantitatively reduced the rate of new bone
formation, the levels of bone resorption markers in the blood
or urine, and the abundance of fibrotic stromal cells that other-
wise populate the marrow compartments of the long bones of
the C1HR mice.(35,36)
A surprising finding was that although inverse agonist treat-
ment in the C1HR mice led to a significant reduction in serum
levels of CTX1, it increased the number and/or size of osteoclasts
lining the bone perimeters (Fig. 4A, Supporting Table S1).
Although the underlying mechanisms are not clear, it is possible
that the bone-resorbing activity of the osteoclasts did not
increase proportionally with an increase in the size and/or num-
ber of these cells. An increase in osteoclast size and/or number
with a concomitant decrease in serum CTX1 was observed previ-
ously by Ko and colleagues(40) in young wild-type mice in
response to 8 weeks of alendronate treatment. Although these
findings appear similar to ours, the upstream mechanisms likely
differ, because the effect involved treatment with a bisphospho-
nate, whereas our current study involves effects on PTHR1
signaling.
We detected no significant change in any bone parameter in
wild-type mice treated with the inverse agonist. The absence of
a skeletal effect in the wild-type mice suggests that the inverse
agonist acts with at least some degree of selectivity on the
PTHR1-H223R variant, relative to on the wild-type PTHR1, and
thus can have efficacy toward that variant without causingmajor
alterations to the normal physiology regulated by the wild-type
PTHR1 and its two endogenous ligands, PTH and PTHrP, acting
in the principal target tissues of bone and kidney. Although a for-
mal toxicological analysis was not performed, there was no sign
of systemic toxicity associated with ligand treatment in either
the wild-type or C1HR mice. In support of this, IA treatment in
either strain of mice resulted in no change in body weight, which
provides at least an initial assessment of systemic drug toxic-
ity(41) (Supporting Fig. S1A), nor a change in serum calcium
(Fig. 4B).
The lengths of the tibias and femurs in the C1HR mice were
~15% shorter than those in wild-type mice, consistent with prior
studies,(31,42) and the mean lengths of the bones in the C1HR
mice tended to increase modestly (3% to 5%) with IA treatment,
although the effects were not significant (Supporting Table S2).
Potential effects on bone length are of interest because impaired
limb development and reduced overall height are prominent
clinical features of JMC.(6) An inverse agonist could conceivably
induce changes in bone length in C1HR mice via actions in the
growth plates, because expression of the PTHR1-H223R trans-
gene is detected at low levels in growth plate chondrocytes of
the C1HR mice,(30) and PTHR1 signaling is well known to play a
major role in growth plate chondrocyte differentiation and
hence bone growth.(39,43–45) We administered the inverse
agonist starting at 7 days of age, and so the analog was present
in the mice during a period of active bone growth. Elucidating
how processes of growth plate maturation and bone growth
might be altered by constitutive PTHR1 signaling and potentially
modulated with an inverse agonist ligand are important research
objectives, given the impact that such altered signaling has on
skeletal development in children with JMC.(6,7)
The recent high-resolution structures of the PTHR1 in partially
active(12) and active-state(13) conformations, together with the
structures obtained for several other family B GPCRs(11,20,46) help
shed light on the mechanisms by which the PTHR1 and these
peptide hormone receptors as a class function. Particularly note-
worthy is the finding that all known JMCmutations map to three
residue positions in the PTHR1: His223, Thr410, and Ile458, which
are each located at the cytosolic base of a TMD helix and at a
position that strongly suggests a critical role in receptor activa-
tion. His223 in TM2 and Thr410 in TM6 are thus seen to be
directly involved in a network of polar residues that acts as a
switch to control the outward movements of the TMD helices
that occur during activation and which lead to the formation of
a cavity on the cytosolic face of the receptor that is used for G
protein coupling.(11,20,46) Ile458 in TM7 is adjacent to Tyr459,
which also participates in the same polar network. A fourth key
residue in this polar network of the PTHR1 is Glu302 in TM3,
which so far has not been associated with JMC. Overall, the dis-
ease phenotype of JMC patients confirms the functional signifi-
cance of this polar network. Although this polar network is
highly conserved in class B GPCRs, we are not aware of another
disorder that is caused by an activating mutation in any of these
other GPCRs, even though mutations introduced at these sites in
several of them have been shown to result in constitutive activity
when tested in transfected cells.(20,47) Whether the apparent
absence of a disease association for these other receptors is
due to poor expression of the constitutively active mutant allele
in the respective target tissue, or by some other overriding factor
is unknown.
The current structural data predict that the PTHR1 mutations
of JMC shift the receptor to an active-state conformation by per-
turbing key molecular interactions that occur within the polar
network at the base of the TMD bundle. The mechanism by
which the binding of the inverse agonist ligand to the receptor’s
extracellularly exposed orthosteric pocket promotes the inactive
receptor conformation is less clear. The dTrp12 modification of
the ligand, which replaces the L-glycine that is conserved at this
position in native PTH and PTHrP agonist ligands, is likely to play
a key role, because it is required for the inverse agonist effect.(27)
Several small-molecule antagonist ligands have been identified
for the PTHR1, but none so far has been reported to function as
an inverse agonist.(29,48,49)
The rarity of JMC is likely to be at least partly explained by a
limited number of sites in the PTHR1 that can result in functional
constitutive activity when mutated; ie, those impacting the con-
served polar residue network comprised of His223, Glu302,
Thr410, and Tyr458. In contrast to the activating mutations of
JMC, heterozygous loss-of-function mutations have been identi-
fied at a number of dispersed sites in the PTHR1 in patients with
defects in tooth eruption.(50) In the very rare homozygous state,
such loss-of-function PTHR1 mutations lead to the perinatal
lethal condition of Blomstrand’s chondrodysplasia,(51) which is
characterized by a hypermineralized skeleton, in contrast to the
low bone mineral density seen in patients with JMC.(6)
In summary, treatment of mice with an inverse agonist ligand
improved at least some of the skeletal and mineral ion defects
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caused by transgenic expression in osteoblasts of a constitutively
active PTHR-H223R allele of JMC. This study is the first demon-
stration that an inverse agonist for the PTHR1 can be effective
in vivo, and thus provides proof-of-concept support for the
notion that such a ligand could potentially be developed as a
therapy for JMC. Although full phenotypic rescue was not
achieved in the current, short-term studies, this was not an
essential goal, given that the transgenic mice utilized here, as
well as other available JMC transgenic mice,(52,53) are not precise
models of the disease, because the mutant allele in the mice is
expressed in a restricted tissue or cell type, eg, bone osteoblasts,
whereas in patients it is expressed in all endogenous PTHR1 tar-
get sites, including bone, kidneys, and the growth-plates. The
current findings nevertheless show that inverse agonist efficacy
in vivo is possible for the mutant PTH receptors of JMC, and they
also suggest that further studies aimed at improving the
receptor-binding properties of such ligands as well as their phar-
macokinetic properties should be important goals of future
research.
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